Purevax Rcpch Felv 10'S

Target species Cats. Indications for use Active immunisation of cats aged 8 weeks and older against: - Feline viral rhinotracheitis to reduce clinical signs. - Calicivirus infection to reduce clinical signs. - Chlamydophila felis infection to reduce clinical signs. - Feline panleucopenia to prevent mortality and clinical signs. - Leukaemia to prevent persistent viraemia and clinical signs of the related disease. Onsets of immunity: Rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components: 1 week after primary vaccination course. Feline leukaemia component: 2 weeks after primary vaccination course. Duration of immunity: -Rhinotracheitis, calicivirosis and panleucopenia components: 1 year after primary vaccination course and 3 years after the last revaccination -Chlamydophila felis and feline leukaemia components: 1 year after the last revaccination. Contra-indications None. Special warnings for each target species Vaccinate healthy animals only. Special precautions for use in animals It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination. Vaccination of FeLV positive cats is of no benefit. Special precautions to be taken by the person administering the product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. This vaccine should not be handled by persons who are immunodeficient or taking immunosuppressive medicinal products. If self-injection occurs, immediate medical advice should be sought and the doctor informed that self-injection with a living chlamydial vaccine has occurred. Adverse reactions Transient apathy and anorexia as well as hyperthermia (lasting usually for 1 or 2 days) were commonly observed during safety and field studies. A local reaction (slight pain at palpation, itching or limited oedema) that disappears within 1 or 2 weeks at most was commonly observed during safety and field studies. A hypersensitivity reaction has been observed uncmmonly in field studies, which may require appropriate symptomatic treatment. Transient hyperthermia and lethargy, sometimes associated with lameness, have been observed 1 to 3 weeks following booster vaccination in adult cats in very rare cases, based on post marketing safety experience. The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s) during the course of one treatment) - common (more than 1 but less than 10 animals treated in 100 animals) - uncommon (more than 1 but less than 10 animals treated in 1,000 animals ) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Use during pregnancy, lactation or lay Do not use during the whole pregnancy and lactation. Interactions Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Boehringer Ingelheim adjuvanted vaccine against rabies. No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.
Vat Rate: 20%